Understanding why pediatric rhabdomyosarcoma tumors don't mature properly

Mediators Of Arrested Differentiation In Pediatric Rhabdomyosarcoma

NIH-funded research St. Jude Children's Research Hospital · NIH-11008924

This study is looking into why rhabdomyosarcoma, a type of cancer that affects kids, doesn't develop like normal muscle cells do, and it's trying to find new ways to help these tumors grow properly so that treatments can work better and have fewer side effects for children.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionSt. Jude Children's Research Hospital NIH-funded
Lab location1 site (Memphis, United States)
Project IDNIH-11008924 on NIH RePORTER

What this research studies

This research investigates the reasons behind the failure of rhabdomyosarcoma (RMS), a common childhood cancer, to undergo normal muscle cell differentiation. By studying the genetic and molecular factors involved, the research aims to uncover new therapeutic strategies that could help these tumors mature and improve treatment outcomes. The approach includes analyzing specific gene expressions and their roles in tumor development, with the goal of designing targeted drug therapies that could enhance differentiation in RMS. This could lead to more effective treatments with fewer long-term side effects for affected children.

Who could benefit from this research

Good fit: Ideal candidates for this research are children under 11 years old diagnosed with rhabdomyosarcoma, particularly those with high-risk forms of the disease.

Not a fit: Patients with rhabdomyosarcoma who are older than 11 years or those with non-high-risk forms of the disease may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to improved treatment options for children with rhabdomyosarcoma, potentially increasing survival rates and reducing long-term complications.

How similar studies have performed: Previous research has shown promise in understanding differentiation in other cancers, suggesting that this approach may yield valuable insights and potential breakthroughs in treating rhabdomyosarcoma.

Where this research is happening

Memphis, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.